Antony Mattessich

Antony is an experienced CEO with over 30 years’ experience in the life science industry. He has an impressive track record in progressing programs from discovery, through clinical development and commercial success, and strong capital markets experience.
Antony has held several senior executive positions where he was instrumental in developing medicines that translate innovative science into meaningful clinical outcomes for patients, with extensive experience in CNS, haemato-oncology, immunology, and metabolics. Most recently, he was President and CEO of Nasdaq-listed Ocular Therapeutix (OCUL), where he launched the company’s lead asset and brought its potential blockbuster in Wet Age-Related Macular Degeneration (wet-AMD) from pre-clinical development into active enrolment in Phase 3.
Prior to Ocular, Antony was Managing Director of Mundipharma and has held senior positions at Novartis and Bristol-Myers Squibb.
Antony holds a BA from the University of California at Berkeley and a Masters in International affairs from Columbia University.